Technical Analysis for GNFT - GENFIT S.A.

Grade Last Price % Change Price Change
grade C 17.46 0.00% 0.00
GNFT closed unchanged on Wednesday, September 18, 2019, on 27 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Up Up
See historical GNFT trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Inside Day Range Contraction 0.00%
Crossed Above 50 DMA Bullish -2.84%
MACD Bullish Centerline Cross Bullish -2.84%
Expansion Pivot Buy Setup Bullish Swing Setup -2.84%
Above Upper BB Strength -2.84%
Gapped Up Strength -2.84%
Upper Bollinger Band Touch Strength -2.84%
Bearish Engulfing Bearish 1.45%
20 DMA Support Bullish 1.45%

Older signals for GNFT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT’s lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide (RESOLVE-IT) in nonalcoholic steatohepatitis, or NASH, considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis, or PBC, a severe chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees.
Medicine Biopharmaceutical Medical Specialties Autoimmune Diseases Hepatitis Hepatology Liver Liver Diseases Non Alcoholic Fatty Liver Disease Steatohepatitis Diagnostic Solutions Primary Biliary Cholangitis Liver Disease Obeticholic Acid
Is GNFT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.25
52 Week Low 14.91
Average Volume 50,808
200-Day Moving Average 0.0
50-Day Moving Average 17.3284
20-Day Moving Average 17.2405
10-Day Moving Average 17.323
Average True Range 0.6079
ADX 12.17
+DI 30.7138
-DI 26.4013
Chandelier Exit (Long, 3 ATRs ) 16.1763
Chandelier Exit (Short, 3 ATRs ) 17.9737
Upper Bollinger Band 17.9364
Lower Bollinger Band 16.5446
Percent B (%b) 0.66
BandWidth 8.072852
MACD Line 0.0551
MACD Signal Line -0.0383
MACD Histogram 0.0935
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.18
Resistance 3 (R3) 18.20 17.98 18.06
Resistance 2 (R2) 17.98 17.80 17.97 18.02
Resistance 1 (R1) 17.72 17.68 17.61 17.70 17.98
Pivot Point 17.50 17.50 17.45 17.49 17.50
Support 1 (S1) 17.24 17.32 17.13 17.22 16.94
Support 2 (S2) 17.02 17.20 17.01 16.90
Support 3 (S3) 16.76 17.02 16.86
Support 4 (S4) 16.74